Galectin-3 mediates aldosterone-induced vascular fibrosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 1, 2013, Pages 67-75

  Calvier, Laurent ^a   Miana, Maria ^b   Reboul, Pascal ^a   Cachofeiro, Victoria ^b   Martinez Martinez, Ernesto ^b   De Boer, Rudolf A ^c   Poirier, Françoise ^d   Lacolley, Patrick ^a   Zannad, Faiez ^a,e   Rossignol, Patrick ^a,e   López Andrés, Natalia ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d CNRS   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

aldosterone; collagen type I; fibrosis; galectin 3; vascular smooth muscle cells

Indexed keywords

ALDOSTERONE; COLLAGEN TYPE 1; GALECTIN 3; MESSENGER RNA; PECTIN; SMALL INTERFERING RNA; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FIBROGENESIS; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RAT; SMOOTH MUSCLE FIBER; VASCULAR FIBROSIS; VASCULAR SMOOTH MUSCLE; VASCULITIS; WILD TYPE;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CELLS, CULTURED; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FIBROSIS; GALECTIN 3; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, WISTAR; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; UP-REGULATION; VASCULAR STIFFNESS;

EID: 84871813952     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300569     Document Type: Article

References (45)

1. Rogerson FM, Fuller PJ. Mineralocorticoid action. Steroids. 2000;65: 61-73.
2. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299-306.
3. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51:161-167.
4. Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663-670.
5. Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens. 2008;17:174-180.
6. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation. 2002;106:2848-2853.
7. Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, Fazal L, Polidano E, Launay JM, Carrier L, Chatziantoniou C, Samuel JL, Delcayre C. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension. 2012;59:1179-1187.
8. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
9. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.
10. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009;119:2471-2479.
11. Safar ME, Millasseau S, Mahmud A, Blacher J. Relations between large artery structure and function and aldosterone. J Hypertens. 2011;29: 1676-1683.
12. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773-779.
13. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616-635.
14. Ahmad N, Gabius HJ, André S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F, Brewer CF. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem. 2004;279:10841-10847.
15. Dennis JW, Pawling J, Cheung P, Partridge E, Demetriou M. UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6 N- acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim Biophys Acta. 2002;1573:414-422.
16. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J. 2004;19:527-535.
17. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int. 2007;31:655-662.
18. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121-3128.
19. Thijssen VL, Hulsmans S, Griffioen AW. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol. 2008;172:545-553.
20. Wan SY, Zhang TF, Ding Y. Galectin-3 enhances proliferation and angiogenesis of endothelial cells differentiated from bone marrow mesenchymal stem cells. Transplant Proc. 2011;43:3933-3938.
21. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28:433-440.
22. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811-817.
23. Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ. Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol. 2001;69:555-564.
24. Martín R, Miana M, Jurado-López R, Martínez- Martínez E, Gómez-Hurtado N, Delgado C, Bartolomé MV, San Román JA, Cordova C, Lahera V, Nieto ML, Cachofeiro V. DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy. PLoS ONE. 2012;7:e41545.
25. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344:1788-1791.
26. Ridley BL, O'Neill MA, Mohnen D. Pectins: structure, biosynthesis, and oligogalacturonide-related signaling. Phytochemistry. 2001;57:929-967.
27. Gunning AP, Bongaerts RJ, Morris VJ. Recognition of galactan components of pectin by galectin-3. FASEB J. 2009;23:415-424.
28. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE. 2011;6:e18683.
29. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol. 2008;14:7386-7391.
30. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, Malorni W, Iacobelli S. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer. 2000;85:545-554.
31. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012;14:74-81.
32. López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, Cachofeiro V, Díez J. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol. 2011;301:H2372-H2382.
33. López-Andrés N, Iñigo C, Gallego I, Díez J, Fortuño MA. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology. 2008;149:4970-4978.
34. Colnot C, Fowlis D, Ripoche MA, Bouchaert I, Poirier F. Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn. 1998;211:306-313.
35. Rossignol P, Bouton MC, Jandrot-Perrus M, Bryckaert M, Jacob MP, Bezeaud A, Guillin MC, Michel JB, Meilhac O. A paradoxical pro-apoptotic effect of thrombin on smooth muscle cells. Exp Cell Res. 2004;299:279-285.
36. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38(3 pt 2): 581-587.
37. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kühl U, Schultheiss HP. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation. 1999;99:2750-2756.
38. Bornstein P, McKay J, Morishima JK, Devarayalu S, Gelinas RE. Regulatory elements in the first intron contribute to transcriptional control of the human alpha 1(I) collagen gene. Proc Natl Acad Sci USA. 1987;84:8869-8873.
39. Lin HM, Pestell RG, Raz A, Kim HR. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene. 2002;21:8001-8010.
40. Briones AM, Arribas SM, Salaices M. Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens. 2010;19:187-194.
41. Ge XN, Bahaie NS, Kang BN, Hosseinkhani MR, Ha SG, Frenzel EM, Liu FT, Rao SP, Sriramarao P. Allergen-induced airway remodeling is impaired in galectin-3-deficient mice. J Immunol. 2010;185:1205-1214.
42. Gekle M, Mildenberger S, Freudinger R, Grossmann C. Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pflugers Arch. 2007;454:403-413.
43. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens. 2012;21:147-156.
44. Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53:258-261.
45. Bunda S, Liu P, Wang Y, Liu K, Hinek A. Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner. Am J Pathol. 2007;171:809-819.